Josef Bruggen
Overview
Explore the profile of Josef Bruggen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bold G, Schnell C, Furet P, McSheehy P, Bruggen J, Mestan J, et al.
J Med Chem
. 2015 Dec;
59(1):132-46.
PMID: 26629594
This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular...
2.
Weisberg E, Manley P, Breitenstein W, Bruggen J, Cowan-Jacob S, Ray A, et al.
Cancer Cell
. 2005 Feb;
7(2):129-41.
PMID: 15710326
The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 <30 nM),...
3.
Manley P, Breitenstein W, Bruggen J, Cowan-Jacob S, Furet P, Mestan J, et al.
Bioorg Med Chem Lett
. 2004 Oct;
14(23):5793-7.
PMID: 15501042
The constitutively active Abl kinase activity of the Bcr-Abl oncoprotein is causative for chronic myelogenous leukemia. Urea derivatives, structurally related to the therapeutic agent STI571, have been identified, which potently...
4.
Manley P, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, et al.
Biochim Biophys Acta
. 2004 Mar;
1697(1-2):17-27.
PMID: 15023347
Initial studies with angiogenesis inhibitors showed little clinical benefit. However, recently reported clinical studies in colorectal cancer have shown that bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody, in...
5.
Leppanen O, Rutanen J, Hiltunen M, Rissanen T, Turunen M, Sjoblom T, et al.
Circulation
. 2004 Feb;
109(9):1140-6.
PMID: 14769706
Background: Platelet-derived growth factor (PDGF) antagonists have demonstrated beneficial effects on neointima formation, but in studies using PDGF inhibitors and extended follow-up, the lesions reoccur. These findings implicate a need...
6.
Manley P, Furet P, Bold G, Bruggen J, Mestan J, Meyer T, et al.
J Med Chem
. 2002 Dec;
45(26):5687-93.
PMID: 12477352
Two readily synthesized anthranilamide, VEGF receptor tyrosine kinase inhibitors have been prepared and evaluated as angiogenesis inhibitors. 2-[(4-Pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide (5) and N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]benzamide (7) potently and selectively inhibit recombinant VEGFR-2 and VEGFR-3...